MacroGenics 'Serves' DART Deal Worth Potential $1B
BioWorld Insight Editor
MacroGenics' DART technology for generating bi‐specific antibodies has attracted a great deal of interest from pharmaceutical and biotechnology companies. In the past couple of years the company has forged alliances with Boehringer Ingelheim, Green Cross (Korea), Pfizer Inc. and Servier. The latest deal brings Servier back to the table.
The French company has just entered an option agreement with MacroGenics for the development and commercialization of Dual‐Affinity Re‐Targeting (DART) products directed at three undisclosed tumor targets.